A carregar...
Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076)
Although bevacizumab (Avastin(®)) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefore, simultaneous blocking of several proangiogenic factors...
Na minha lista:
| Publicado no: | Biomolecules |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7356919/ https://ncbi.nlm.nih.gov/pubmed/32560565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom10060919 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|